• Array BioPharma’s mCRC therapy gets breakthrough status pharmaceutical-technology
    August 10, 2018
    Array BioPharma has received breakthrough therapy designation from the US Food and Drug Administration (FDA) to use encorafenib (Braftovi) in combination with binimetinib (Mektovi) and cetuximab for the treatment of metastatic colorectal cancer (mCRC).
PharmaSources Customer Service